New Two-Drug attack on rare blood cancer shows promise
NCT ID NCT03410875
Summary
This study is testing whether combining two drugs—an oral targeted therapy (vemurafenib) and an immunotherapy infusion (obinutuzumab)—can effectively treat adults with hairy cell leukemia who haven't had any prior treatment. The goal is to achieve a complete remission, meaning no detectable cancer after treatment. The trial will enroll up to 30 patients to see if this combination is a viable option for controlling this rare blood cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, 10604, United States
-
Memorial Sloan Kettering at Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Yale University
New Haven, Connecticut, 06511, United States
Conditions
Explore the condition pages connected to this study.